ArticleFrontiers in neurology2025
Low-dose statins combined with repetitive transcranial magnetic stimulation reduce post-stroke depression.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effectiveness of statins in preventing post-stroke depression (PSD) remains controversial. Lower testosterone levels caused by statins could potentially increase the risk of PSD. Low-dose statins could offer better benefits due to their lesser impact on testosterone levels. Repetitive transcranial magnetic stimulation (rTMS) has been shown to reduce PSD in the acute stage. The combination of low-dose statins and rTMS may provide a promising therapeutic option for patients with PSD. Methods: Data were collected from ischemic stroke patients. Unsupervised machine learning methods were employed to explore the risk factor of PSD. Our prospective cohort study collected data from ischemic stroke patients over 3 years. The patients' conditions determined the prescription of statins. The outcomes measured included the incidence of PSD, favorable functional outcome (FFO) at 6- and 12-months post-onset. Results: A total of 545 patients were included in the study. The mean age was 60.99 ± 12.768 years, and 31.9% of the participants were female. The combination of low-dose statins and rTMS subgroup had the lowest incidence of PSD at both 6 and 12 months ( Conclusion: The combination of statins and the rTMS group related the lower incidence of PSD in stroke patients. Combining low-dose statins and rTMS could reduce PSD and further improve the prognosis of ischemic stroke patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.